Cargando...
Role of zoledronic acid in the prevention and treatment of osteoporosis
Taken once a year, intravenous zoledronic acid (Zol) (Reclast(®) or Aclasta(®)) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In gluco...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3095556/ https://ncbi.nlm.nih.gov/pubmed/21594000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S7282 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|